Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 3/20 | 0.38 |
| ▸ | CNR2 | P34972 | 3/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.37 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.37 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | F10 | P00742 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23745530 | 0.92 | CNR1 (0.45) | CNR1CNR2ALDH1A1HPGD | |
| SCHEMBL23745525 | 0.91 | SMYD3 (0.42) | SMYD3CNR1CNR2PDE4BPDE4D | |
| SCHEMBL23745774 | 0.91 | SMYD3 (0.42) | SMYD3CNR1CNR2PDE4BPDE4D | |
| Hydrochloric Acid SCHEMBL23722115 | 0.90 | SMYD3 (0.41) | SMYD3CNR1CNR2PDE4BPDE4D | |
| Hydrochloric Acid SCHEMBL23722075 | 0.90 | SMYD3 (0.41) | SMYD3CNR1CNR2PDE4BPDE4D | |
| SCHEMBL23745466 | 0.89 | ALDH1A1 (0.39) | SMYD3CNR1CNR2ALDH1A1KDM4E | |
| SCHEMBL23745500 | 0.88 | CHRM4 (0.38) | SMYD3CNR1CNR2ALDH1A1KDM4E | |
| SCHEMBL23745786 | 0.88 | CNR1 (0.44) | SMYD3CNR1CNR2ALDH1A1DCUN1D1 | |
| Hydrochloric Acid SCHEMBL23721878 | 0.87 | CHRM4 (0.38) | SMYD3CNR1CNR2ALDH1A1KDM4E | |
| Hydrochloric Acid SCHEMBL23721982 | 0.87 | CNR1 (0.44) | SMYD3CNR1CNR2ALDH1A1DCUN1D1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210246115-A1 | ANTI-INFECTIVE HETEROCYCLIC COMPOUNDS AND USES THEREOF | BIOIMICS AB (SE) | 2021-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210246115-A1 | ANTI-INFECTIVE HETEROCYCLIC COMPOUNDS AND USES THEREOF | FDPS, FPR1, F12 | SMYD3 3773/4885CNR1 1651/4885CNR2 2528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.